Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Voyager Therapeutics, Inc. 

NEW YORK, Jan. 29, 2021 (GLOBE NEWSWIRE) – Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. (“Voyager” or the “Company”). ) (NASDAQ: VYGR) in the U.S. District Court for the Eastern District of New York on behalf of a class consisting of all investors who purchased or otherwise acquired Voyager securities between June 1, 2017 and November 9, 2020, including Voyager (the lesson”).

All Investors who bought stocks from Voyager Therapeutics, Inc. and any losses incurred are strongly recommended to contact the company immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. For more information on the promotion, visit our website at www.whafh.com.

If you have suffered a loss in Voyager Therapeutics, Inc. stock, she can, no later than March 24, 2021, Ask the court to appoint you as the lead plaintiff in the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in Voyager Therapeutics, Inc.

CLICK HERE TO JOIN CASE

Voyager, a clinical-stage gene therapy company, is focused on developing therapies for patients with severe neurological disorders. The company’s preclinical programs include VY-HTT01 for Huntington’s disease.

On June 1, 2017, Voyager issued a press release announcing that VY-HTT01 was selected as a lead clinical candidate for the treatment of Huntington’s disease. The press release also indicated that [p]Reclinical pharmacology and toxicology studies [were] runs with VY-HTT01 to support the submission of a New Investigational Medicinal Product (IND) application in 2018. “

In September 2020, Voyager filed with the US Food and Drug Administration (“FDA”) an application for a new investigational drug (“IND”) for VY-HTT01 for the treatment of Huntington’s disease.

On October 12, 2020, Voyager issued a press release announcing that it had received “Feedback from the US Food and Drug Administration (FDA) on the filing of Investigational New Drug (IND) for VY-HTT01 for the treatment of HD Disease has received “. In particular, Voyager has notified investors that it does
was informed that the IND has been placed on clinical hold pending resolution of certain Chemistry, Manufacturing and Control (CMC) issues. “

On November 9, 2020, Voyager released a press release announcing the company’s financial results and company updates for the third quarter of 2020. In the press release, the company announced that “Voyager has recently received written feedback from the FDA regarding its IND filing for VY-HTT01
Requesting additional information on specific CMC topics, including drug tolerability and the characterization of drug substances and products. “

In the news, Voyager’s share price fell $ 2.60 per share, or 23.21%, to close at $ 8.60 per share on November 10, 2020.

Wolf Haldenstein has extensive experience prosecuting class and derivative disputes in state and federal courts and appeals courts across the country. The firm has lawyers in various fields of activity; and offices in New York, Chicago and San Diego. This law firm’s reputation and expertise in shareholder and other class disputes has been recognized repeatedly by the courts who have appointed them to key positions in complex securities multiple district and consolidated litigation.

If you would like to discuss this campaign or if you have any questions about your rights and interests in this case, please contact Wolf Haldenstein immediately by telephone at (800) 575-0735, by email at classmember@whafh.com or visit our website on www.whafh.com.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, director of case and financial analysis
Email: gstone@whafh.com, kcooper@whafh.com, or classmember@whafh.com
Tel .: (800) 575-0735 or (212) 545-4774

This press release may be viewed as a solicitor’s advertisement in some jurisdictions under applicable laws and ethical rules.

Comments are closed.